Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of TRK-820 are to be evaluated in the treatment of intractable
pruritus in patients with Chronic Liver Disease by administering 2.5, 5 and 10 microg of this
drug or placebo for 28 days in four groups with a design of randomized, double-blind,
parallel-group comparison. In addition, the plasma concentrations of TRK-820 and its primary
metabolites are to be determined.